Security
MapLight Therapeutics, Inc. Common Stock · MPLT
MPLTNASDAQCommon stockCurrentCIK 1770069Updated Oct 19, 2026
Name history
Alvarado Therapeutics, Inc. · through Mar 22, 2019
MPLT price & chart
Loading TradingView…
NASDAQ:MPLT on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.
In the news
MapLight Therapeutics Announces $150 Million Private Placement Financing ↗
Seeking Alpha
MapLight: 'Hold' Rating On ML-007C-MA In Schizophrenia And 2nd Half 2027 ADP Data Readout ↗
MapLight co-founder is joint winner of 2026 Nobel Prize in Medicine ↗
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 257,222,000Source | — | 368,348,000Source | — | 418,788,000Source | — | 479,512,000Source | 136,916,000Source |
| Property, Plant and Equipment, NetUSD | 859,000Source | — | 828,000Source | — | 968,000Source | — | 1,095,000Source | 1,207,000Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 64,146,000Source | — | 71,633,000Source | — | 55,707,000Source | — | 46,729,000Source | 38,253,000Source |
| Assets, CurrentUSD | 245,306,000Source | — | 318,788,000Source | — | 327,228,000Source | — | 324,670,000Source | 114,602,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 18,138,000Source | — | 14,063,000Source | — | 17,115,000Source | — | 19,567,000Source | 5,807,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,710,000Source | — | 1,668,000Source | — | 5,259,000Source | — | 5,488,000Source | 6,354,000Source |
| Other Assets, NoncurrentUSD | 5,140,000Source | — | 241,000Source | — | 36,000Source | — | 59,000Source | 3,166,000Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 23,706,000Source | — | 20,049,000Source | — | 18,954,000Source | — | 21,140,000Source | 21,721,000Source |
| Stockholders’ equity: | ||||||||
| Common Stock, Value, IssuedUSD | 0Source | — | 5,000Source | — | 5,000Source | — | 5,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -280,972,000Source | — | -481,380,000Source | — | -421,188,000Source | — | -360,520,000Source | -199,368,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 46,000Source | — | -944,000Source | — | -883,000Source | — | -228,000Source | 163,000Source |
| Stockholders' Equity Attributable to ParentUSD | -274,177,000Source | -172,370,000Source | 348,299,000Source | -245,062,000Source | 399,834,000Source | -215,829,000Source | 458,372,000Source | -193,628,000Source |
| Additional Paid in Capital, Common StockUSD | 6,749,000Source | — | 830,618,000Source | — | 821,900,000Source | — | 819,115,000Source | 5,577,000Source |
| Liabilities and EquityUSD | 257,222,000Source | — | 368,348,000Source | — | 418,788,000Source | — | 479,512,000Source | 136,916,000Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 18,562,000Source | — | 19,294,000Source | — | 14,283,000Source | — | 16,229,000Source | 15,920,000Source |
| Operating Lease, Liability, CurrentUSD | 862,000Source | — | 1,232,000Source | — | 920,000Source | — | 891,000Source | 778,000Source |
| Accounts Payable, CurrentUSD | 2,446,000Source | — | 2,052,000Source | — | 3,188,000Source | — | 3,289,000Source | 1,912,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,144,000Source | — | 755,000Source | — | 4,671,000Source | — | 4,911,000Source | 5,801,000Source |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | 14,048,000Source | — | 16,010,000Source | — | 10,175,000Source | — | 12,049,000Source | 9,991,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 227,200,000Source | — | — | — | — | — | 453,100,000Source | — |
| Deferred Revenue, CurrentUSD | 1,206,000Source | — | — | — | 0Source | — | 0Source | 3,239,000Source |
| Short-term InvestmentsUSD | 163,022,000Source | — | 233,092,000Source | — | 254,406,000Source | — | 258,374,000Source | 70,542,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,636,000Source | 212,000Source | 36,006,000Source | 1,080,000Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -111,000Source | -1,050,000Source | 1,384,000Source | -1,345,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -51,178,000Source | -25,550,000Source | -138,137,000Source | -78,815,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 67,007,000Source | 37,500,000Source | -323,207,000Source | -80,788,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 24,000Source | — | 473,000Source | 770,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -6,851,000Source | -47,000Source | 469,820,000Source | 118,060,000Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 125,000Source | 354,000Source | 8,626,000Source | 148,000Source | 9,636,000Source | 212,000Source | 36,006,000Source | 1,080,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 227,200,000Source | — | — | — | — | — | 453,100,000Source | — |
| DepreciationUSD | — | — | 100,000Source | 200,000Source | — | — | 162,000Source | 166,000Source | 578,000Source | 701,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | -986,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -4,000Source | — | -7,000Source | -59,000Source |
| General and Administrative ExpenseUSD | — | — | 4,404,000Source | 4,080,000Source | 10,113,000Source | 3,817,000Source | 10,819,000Source | 3,756,000Source | 30,734,000Source | 14,423,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 1,549,000Source | 1,081,000Source | 2,349,000Source | 688,000Source | 2,472,000Source | 811,000Source | 5,518,000Source | 4,504,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,418,000Source | -19,016,000Source | -60,192,000Source | -29,845,000Source | -60,668,000Source | -22,340,000Source | -161,152,000Source | -77,580,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,080,000Source | 1,878,000Source | — | — | — | — | 7,931,000Source | 5,366,000Source |
| Operating ExpensesUSD | — | — | 31,498,000Source | 20,894,000Source | 63,548,000Source | 30,663,000Source | 64,503,000Source | 23,543,000Source | 169,083,000Source | 82,946,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 531,000Source | 797,000Source | 1,007,000Source | 130,000Source | 1,363,000Source | 392,000Source | 2,413,000Source | 1,848,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | 52,000Source | 5,021,000Source | 2,190,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 408,234,000Source | 125,018,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 285,000Source | 294,000Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -31,498,000Source | -20,894,000Source | -63,548,000Source | -30,663,000Source | -64,503,000Source | -23,543,000Source | -169,083,000Source | -82,946,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 531,000Source | 797,000Source | 1,007,000Source | 130,000Source | 1,363,000Source | 392,000Source | 2,413,000Source | 1,848,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,418,000Source | -19,016,000Source | -60,192,000Source | -29,845,000Source | -60,668,000Source | -22,340,000Source | -161,152,000Source | -77,580,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -37.18Source | -25.08Source | -1.32Source | -39.11Source | -1.34Source | -29.33Source | -18.56Source | -105.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -37.18Source | -25.08Source | -1.32Source | -39.11Source | -1.34Source | -29.33Source | -18.56Source | -105.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 791,127Source | 758,204Source | 45,431,359Source | 763,044Source | 45,276,763Source | 761,598Source | 8,680,741Source | 736,178Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 791,127Source | 758,204Source | 45,431,359Source | 763,044Source | 45,276,763Source | 761,598Source | 8,680,741Source | 736,178Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 4,404,000Source | 4,080,000Source | 10,113,000Source | 3,817,000Source | 10,819,000Source | 3,756,000Source | 30,734,000Source | 14,423,000Source |
| Investment Income, InterestUSD | — | — | 1,549,000Source | 1,081,000Source | 2,349,000Source | 688,000Source | 2,472,000Source | 811,000Source | 5,518,000Source | 4,504,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,080,000Source | 1,878,000Source | — | — | — | — | 7,931,000Source | 5,366,000Source |
| Operating ExpensesUSD | — | — | 31,498,000Source | 20,894,000Source | 63,548,000Source | 30,663,000Source | 64,503,000Source | 23,543,000Source | 169,083,000Source | 82,946,000Source |
| Research and Development ExpenseUSD | — | — | 27,094,000Source | 16,814,000Source | 53,435,000Source | 26,846,000Source | 53,684,000Source | 19,787,000Source | 138,349,000Source | 68,523,000Source |
Offerings
Registration 333-298837
Filing attachments
ormp-ex99_1.htm · SCHEDULE 13G · 2026-08-20
Exhibit 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: August 20, 2026 NAN FUNG GROUP HOLDINGS LIMITED By: /s/ Tang Chun Wai Nelson …
Read attachment ↗d48818dex41.htm · 8-K · 2026-08-13
EX-4.1 2 d48818dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (I…
Read attachment ↗d48818dex991.htm · 8-K · 2026-08-13
EX-99.1 5 d48818dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027 Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irri…
Read attachment ↗d48818dex992.htm · 8-K · 2026-08-13
EX-99.2 6 d48818dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 MapLight Therapeutics Announces $150 Million Private Placement Financing SAN FRANCISCO and BOSTON, August 13, 2026 (GLOBE NEWSWIRE) - MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited inve…
Read attachment ↗d139086dex991.htm · 8-K · 2026-07-27
EX-99.1 2 d139086dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Topline Data from Phase 2 ZEPHYR Trial Evaluating ML-007C-MA in Schizophrenia July 27, 2026 Safe Harbor and Forward-Looking Statements This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company”, or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, trade names and…
Read attachment ↗d139086dex992.htm · 8-K · 2026-07-27
EX-99.2 3 d139086dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015) Cognitive performance was improved (ES…
Read attachment ↗